IONS - アイオニス・ファ―マシュ―ティカルズ (Ionis Pharmaceuticals Inc.) アイオニス・ファ―マシュ―ティカルズ

 IONSのチャート


 IONSの企業情報

symbol IONS
会社名 Ionis Pharmaceuticals Inc (アイオニス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イオニス・ファーマシューティカルズ(Ionis Pharmaceuticals Inc.)(旧名:Isis Pharmaceuticals Inc.)はリボ核酸標的(RNA標的)薬の発見・開発会社である。同社はアンチセンス薬の発見・開発に焦点を当てる。同社のアンチセンス薬は、心血管、代謝、神経疾患を含む重症・希少疾患、及び癌等疾患の治療に使用される。Volanesorsenは、家族制カイロミクロン血症(FCS)と呼ばれる遺伝子疾患を持つ患者及び限局性脂肪異栄養症を持つ患者を含む高トリグリセリドレベルを有する患者の治療のための薬である。同社は、後期フェーズIII薬、nusinersen、volanesorsenとIONIS-TTRを市場に導入することに焦点を当てる。同社の脂質低下製品KYNAMRO(ミポメルセンナトリウム)注射液は、米国市場でホモ接合型家族性高コレステロール血症(HoFH)を持つ患者に使用される。同社の製品はまたAlicaforsen、IONIS-DMPK-2.5、PlazomicinとIONIS-GCGRが含まれる。  アイオニス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主に治療用新化合物の発見・製造・販売に従事。同社製品には遺伝性高脂血症治療薬の「KYNAMRO」や、高トリグリセリド血症治療薬の「ISIS-APOCIIIRx」や「ISIS-FXIRx」がある。本社はカリフォルニア州サンディエゴ。   Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
本社所在地 2855 Gazelle Court Carlsbad CA 92010 USA
代表者氏名 Stanley T. Crooke スタンリーT.クルーク
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 760-931-9200
設立年月日 32509
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 547人
url www.ionispharma.com
nasdaq_url https://www.nasdaq.com/symbol/ions
adr_tso
EBITDA EBITDA(百万ドル) -32.05600
終値(lastsale) 44.96
時価総額(marketcap) 6171834858.72
時価総額 時価総額(百万ドル) 6203.408
売上高 売上高(百万ドル) 555.37600
企業価値(EV) 企業価値(EV)(百万ドル) 4848.796
当期純利益 当期純利益(百万ドル) 67.31500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ionis Pharmaceuticals Inc revenues increased 19% to $262.2M. Net loss increased from $2.2M to $41.8M. Revenues reflect Akcea Therapeutics segment increase from $11.8M to $35.4M. Higher net loss reflects Ionis core segment income decrease of 63% to $40.5M Akcea Therapeutics segment loss increase of 13% to $93.8M Elimination of Intercompany Activity segment loss totaling $379K vs. income of $60K.

 IONSのテクニカル分析


 IONSのニュース

   AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA  2020/09/04 23:49:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akcea Therapeutics, Inc. (NasdaqGS: AKCA) to Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS). Under the terms of the proposed transaction, shareholders of Akcea will receive only $18.15 in cash for each share of Akcea that they own. KSF is seeking to determine whether this consideration and the process that led t
   Ionis to present at upcoming virtual investor conferences  2020/09/03 11:05:00 PR Newswire
CARLSBAD, Calif., Sept. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences: Wells Fargo 2020 Healthcare Conference on…
   INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA  2020/09/01 21:05:00 Benzinga
NEW YORK , Sept. 1, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Akcea Therapeutics, Inc. ("Akcea" or the "Company") (Nasdaq: AKCA) relating to its sale to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, Akcea shareholders will receive $18.15 in cash for each share of Akcea common stock owned. … Full story available on Benzinga.com
   Akcea Therapeutics Rallies After Majority Owner Ionis Agrees To Buy Remaining Stake  2020/08/31 14:26:58 Benzinga
Akcea Therapeutics Inc (NASDAQ: AKCA ) shares were rallying strongly Monday following a buyout deal. The Ionis, Akcea Deal Terms: Akcea and its majority owner Ionis Pharmaceuticals Inc (NASDAQ: IONS ) announced a definitive agreement under which Ionis will acquire the 24% stake in Akcea it does not already own for $18.15 per share — about 60% higher than Akcea's Friday closing price. The total transaction value is about $500 million. The deal has been approved by the boards of both companies and … Full story available on Benzinga.com
   Ionis Pharmaceuticals to hold cardio-renal franchise webcast  2020/08/26 11:05:00 PR Newswire
CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise. The approximately 90-minute webcast will include…
   Ionis Pharmaceuticals to hold cardio-renal franchise webcast  2020/08/26 11:05:00 PR Newswire
CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise. The approximately 90-minute webcast will include…
   Earnings Scheduled For August 5, 2020  2020/08/05 08:20:31 Benzinga
Companies Reporting Before The Bell • AmerisourceBergen Inc. (NYSE: ABC ) is expected to report quarterly earnings at $1.56 per share on revenue of $44.66 billion. • Advanced Energy Indus Inc. (NASDAQ: AEIS ) is expected to report quarterly earnings at $0.81 per share on revenue of $318.21 million, • ALLETE Inc. (NYSE: ALE ) is expected to report quarterly earnings at $0.67 per share on revenue of $290.75 million. • Allogene Therapeutics Inc. (NASDAQ: ALLO ) is expected to report earnings for its second quarter. • Ares Management Inc. (NYSE: ARES ) is estimated to report quarterly earnings at $0.38 per share on revenue of $343.00 million. • Astec Industries Inc. (NASDAQ: ASTE ) is estimated to report quarterly earnings at $0.05 per share on revenue of $228.97 million. • Athene Holding Inc. (NYSE: ATH ) is estimated to report quarterly earnings at $1.71 per share on revenue of $1.00 billion. • Axcella Health Inc. (NASDAQ: AXLA ) is expected to report earnings for its second quarter. • Brainstorm Cell Inc.
   Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast  2020/07/22 11:05:00 PR Newswire
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 5th at 11:30 a.m. Eastern Time…
   Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates  2020/05/06 13:45:05 Zacks Investment Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 9.09% and -16.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Earnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline  2020/04/29 16:34:40 Zacks Investment Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates  2020/05/06 13:45:05 Zacks Investment Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 9.09% and -16.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Earnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline  2020/04/29 16:34:40 Zacks Investment Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group  2020/04/22 15:08:00 Zacks Investment Research
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
   Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast  2020/04/22 11:05:00 PR Newswire
CARLSBAD, Calif., April 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 6th at 11:30 a.m. Eastern Time to discuss its first quarter 2020 financial results and report on pipeline and business progress….
   Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease  2020/04/20 11:05:00 PR Newswire
CARLSBAD, Calif., April 20, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that its partner Roche, also known as Genentech in the United States, has completed enrollment for GENERATION HD1, a global Phase 3 study…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アイオニス・ファ―マシュ―ティカルズ IONS Ionis Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)